This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maciá, M. D. Articles by Oliver, A. Search for Related Content PubMed PubMed Citation Articles by Maciá, M. D. Articles by Oliver, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2006, p. 975-983, Vol. 50, No. 3
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.3.975-983.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable Pseudomonas aeruginosa

Servicio de Microbiología,¹ Servicio de Anatomía Patológica, Hospital Son Dureta, Palma de Mallorca, Spain²

Received 21 October 2005/ Returned for modification 4 December 2005/ Accepted 21 December 2005

Hypermutable Pseudomonas aeruginosa strains are found with high frequency in the lungs of patients with chronic infections and are associated with high antibiotic resistance rates. The in vivo consequences of hypermutation for treatment in a mouse model of lung infection using strain PAO1 and its hypermutable derivative PAOmutS are investigated. Groups of 30 mice were treated for 3 days with humanized regimens of ciprofloxacin (CIP), tobramycin (TOB), CIP plus TOB, or placebo, and mortality, total lung bacterial load, and 4x- and 16x-MIC mutants were recorded. The rates of mutation and the initial in vivo frequencies of mutants (at the onset of treatment) were also estimated and the in vitro- and in vivo-selected mutants characterized. Since both strains had identical MICs, the same pharmacokinetic/pharmacodynamic (PK/PD) parameters were obtained: area under the 24-h concentration-time curve (fAUC)/MIC = 385 for CIP and maximum concentration of drug in serum (fC_max)/MIC = 19 for TOB. Despite adequate PK/PD parameters, persistence of high bacterial numbers and amplification (50,000-fold) of resistant mutants (MexCD-OprJ hyperexpression) were documented with CIP treatment for PAOmutS, in contrast to complete resistance suppression for PAO1 (P < 0.01), showing that conventional PK/PD parameters may not be applicable to infections by hypermutable strains. On the other hand, the efficacy of TOB monotherapy in terms of mortality reduction and bacterial load was very low regardless of the strain but not due to resistance development, since mutants were not selected for PAO1 and were only modestly amplified for PAOmutS. Finally, the CIP-plus-TOB combination was synergistic, further reducing mortality and bacterial load and completely preventing resistance even for PAOmutS (P < 0.01 compared to monotherapy), showing that it is possible to suppress resistance selection in infections by hypermutable P. aeruginosa using appropriate combined regimens.

This article has been cited by other articles:

• Waine, D. J., Honeybourne, D., Smith, E. G., Whitehouse, J. L., Dowson, C. G. (2008). Association between Hypermutator Phenotype, Clinical Variables, Mucoid Phenotype, and Antimicrobial Resistance in Pseudomonas aeruginosa. J. Clin. Microbiol. 46: 3491-3493 [Abstract] [Full Text]  
• Jeannot, K., Elsen, S., Kohler, T., Attree, I., van Delden, C., Plesiat, P. (2008). Resistance and Virulence of Pseudomonas aeruginosa Clinical Strains Overproducing the MexCD-OprJ Efflux Pump. Antimicrob. Agents Chemother. 52: 2455-2462 [Abstract] [Full Text]  
• Mulcahy, H., O'Callaghan, J., O'Grady, E. P., Macia, M. D., Borrell, N., Gomez, C., Casey, P. G., Hill, C., Adams, C., Gahan, C. G. M., Oliver, A., O'Gara, F. (2008). Pseudomonas aeruginosa RsmA Plays an Important Role during Murine Infection by Influencing Colonization, Virulence, Persistence, and Pulmonary Inflammation. Infect. Immun. 76: 632-638 [Abstract] [Full Text]  
• Henrichfreise, B., Wiegand, I., Luhmer-Becker, I., Wiedemann, B. (2007). Development of Resistance in Wild-Type and Hypermutable Pseudomonas aeruginosa Strains Exposed to Clinical Pharmacokinetic Profiles of Meropenem and Ceftazidime Simulated In Vitro. Antimicrob. Agents Chemother. 51: 3642-3649 [Abstract] [Full Text]  
• Plasencia, V., Borrell, N., Macia, M. D., Moya, B., Perez, J. L., Oliver, A. (2007). Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents. Antimicrob. Agents Chemother. 51: 2574-2581 [Abstract] [Full Text]  
• Kenna, D. T., Doherty, C. J., Foweraker, J., Macaskill, L., Barcus, V. A., Govan, J. R. W. (2007). Hypermutability in environmental Pseudomonas aeruginosa and in populations causing pulmonary infection in individuals with cystic fibrosis. Microbiology 153: 1852-1859 [Abstract] [Full Text]  
• Montanari, S., Oliver, A., Salerno, P., Mena, A., Bertoni, G., Tummler, B., Cariani, L., Conese, M., Doring, G., Bragonzi, A. (2007). Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology 153: 1445-1454 [Abstract] [Full Text]  
• Mena, A., Macia, M. D., Borrell, N., Moya, B., de Francisco, T., Perez, J. L., Oliver, A. (2007). Inactivation of the Mismatch Repair System in Pseudomonas aeruginosa Attenuates Virulence but Favors Persistence of Oropharyngeal Colonization in Cystic Fibrosis Mice. J. Bacteriol. 189: 3665-3668 [Abstract] [Full Text]